A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Novartis Pharmaceuticals
Novartis Pharmaceuticals
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
986 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Novartis Investigative Site
CABA, Buenos Aires, Argentina
- Novartis Investigative Site
CABA, Buenos Aires, Argentina
- Novartis Investigative Site
CABA, Buenos Aires, Argentina
- Novartis Investigative Site
CABA, Buenos Aires, Argentina
- Novartis Investigative Site
CABA, Buenos Aires, Argentina
- Novartis Investigative Site
CABA, Buenos Aires, Argentina
- Novartis Investigative Site
CABA, Buenos Aires, Argentina
- Novartis Investigative Site
CABA, Buenos Aires, Argentina
- Novartis Investigative Site
CABA, Buenos Aires, Argentina
- Novartis Investigative Site
Caba, Buenos Aires, Argentina
- Novartis Investigative Site
Lanus, Buenos Aires, Argentina
- Novartis Investigative Site
Mar del Plata, Buenos Aires, Argentina
- Novartis Investigative Site
Ramos Mejía, Buenos Aires, Argentina
- Novartis Investigative Site
San Martín, Buenos Aires, Argentina
- Novartis Investigative Site
Córdoba, Córdoba Province, Argentina
- Novartis Investigative Site
Córdoba, Córdoba Province, Argentina
- Novartis Investigative Site
Córdoba, Córdoba Province, Argentina
- Novartis Investigative Site
Córdoba, Córdoba Province, Argentina
- Novartis Investigative Site
Córdoba, Córdoba Province, Argentina
- Novartis Investigative Site
Concepcion Uruguay, Entre Ríos Province, Argentina
- Novartis Investigative Site
Paraná, Entre Ríos Province, Argentina
- Novartis Investigative Site
Formosa, Formosa Province, Argentina
- Novartis Investigative Site
Mendoza, Mendoza Province, Argentina
- Novartis Investigative Site
Salta, Salta Province, Argentina
- Novartis Investigative Site
San Miguel de Tucumán, San Miguel de Tucuman, Argentina
- Novartis Investigative Site
Grandero Baigorria, Santa Fe Province, Argentina
- Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
- Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
- Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
- Novartis Investigative Site
Santa Fe, Santa Fe Province, Argentina
- Novartis Investigative Site
San Miguel, Tucumán Province, Argentina
- Novartis Investigative Site
San Miguel Tucuman, Tucumán Province, Argentina
- Novartis Investigative Site
Buenos Aires, Argentina
- Novartis Investigative Site
Buenos Aires, Argentina
- Novartis Investigative Site
Buenos Aires, Argentina
- Novartis Investigative Site
Caba, Argentina
- Novartis Investigative Site
Caba, Argentina
- Novartis Investigative Site
Capital Federal, Argentina
- Novartis Investigative Site
Corrientes, Argentina
- Novartis Investigative Site
Córdoba, Argentina
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 9 Mar 2023
- Primary completion
- 16 Apr 2029
- Completion
- 16 Apr 2029
- Last update posted
- 6 Jul 2026
- Registered enrollment
- 14,012
- Registry id
- NCT05739383
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.